Funded Biotechnology Startups in Ireland
Disclosed round sizes in Ireland biotech skew heavily toward a single outlier: Normax Biomed’s $301M (2022-07-11) dwarfs the next-largest disclosed amount,…
Disclosed round sizes in Ireland biotech skew heavily toward a single outlier: Normax Biomed’s $301M (2022-07-11) dwarfs the next-largest disclosed amount, Perrigo’s $2.6B (2022-04-20) is the largest disclosed in the dataset, followed by Trinity Biotech’s $45M (2022-04-11) and Vivasure Medical’s $32M (2023-03-13). At the other end, the smallest disclosed round is Ovagen’s $2M (2024-10-29) and Amara Therapeutics’ $2M (2023-05-08), both sitting on the low floor.
Geographically, Dublin appears repeatedly (e.g., Neuromod Devices $11M on 2025-03-11; Somaí Pharmaceuticals $4M on 2024-04-01; Carrick Therapeutics $35M on 2022-12-01), while multi-entry clustering shows up in the newest window: four rows have round dates in 2025 (2025-03-11 through 2025-11-04). Stage disclosures are frequently incomplete: 8 of 24 rows are “undisclosed” and 5 of 24 are “Series Unknown,” with only the remainder carrying explicit named stages (e.g., Series A/B/D). Rounds span 2020-06-03 (Shorla Pharma $8M) through 2026-01-07 (Luminate Medical $21M).
Most recent rounds
24 shownRelated listings
Frequently asked
Which disclosed round looks most like an outlier in this Ireland biotech set, and how far above the rest is it?
Perrigo’s Post-IPO Debt round is the largest disclosed amount at $2.6B on 2022-04-20, far above the next-highest disclosed rounds in the table such as Trinity Biotech’s $45M (2022-04-11) and Vivasure Medical’s $32M (2023-03-13). On the low end, the floor of disclosed amounts is $2M, appearing for Ovagen (2024-10-29) and Amara Therapeutics (2023-05-08).
Do round dates cluster into a narrow recent window, or are they evenly spread across years?
The most recent cluster is 2025, where four entries have round dates between 2025-03-11 (Neuromod Devices) and 2025-11-04 (Konree Innovation). Outside that, the dataset spans 2020-06-03 (Shorla Pharma $8M) through 2026-01-07 (Luminate Medical $21M), indicating more of a multi-year pattern than a single tight spike.
Is Dublin over-represented among companies in this list compared with other Irish cities?
Dublin shows up across multiple rounds, including Neuromod Devices ($11M on 2025-03-11), Somaí Pharmaceuticals ($4M on 2024-04-01), Carrick Therapeutics ($35M on 2022-12-01), and Perrigo ($2.6B on 2022-04-20). Other cities like Galway, Cork, and Galway also recur, but Dublin is one of the clearest repeated hubs in the displayed rows.
How much of the dataset lacks clear disclosed stage information (Series Unknown/undisclosed), and what’s the implication for reading stage trends?
Out of 24 rows, 8 list the amount as “undisclosed” and 5 are labeled “Series Unknown,” meaning 13 rows do not provide a clear combination of disclosed size and named stage. The remaining rows include explicit stages such as Series A (e.g., Luminate Medical $21M on 2026-01-07; Ovagen $2M on 2024-10-29), Series B (e.g., Neuromod Devices $11M on 2025-03-11), and Series D (Vivasure Medical $32M on 2023-03-13).
Within the latest dates shown, are there any notable size patterns or missing disclosure patterns?
In the newest entries, disclosed amounts include Luminate Medical’s $21M (2026-01-07) and Antler Bio’s $4M (2025-06-14), while some nearby rounds are not disclosed (Konree Innovation on 2025-11-04 and Nemysis on 2025-03-18). This mix suggests both meaningful disclosed financing and several “undisclosed”/unclear-stage records close to the top of the date range.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.